Korea United Pharm (033270) Fundamentals 2026 — P/E 6.4x, Revenue Analysis | SniperIQ
Korea United Pharm (033270) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩245.2B, trading at ₩16980.00 on the KSC. This SniperIQ fundamentals page covers Korea United Pharm's valuation (P/E 6.4x, P/B 0.6x), profitability (net margin 13.6%), revenue (₩288.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Korea United Pharm's market cap?
Korea United Pharm (033270) has a market capitalization of approximately ₩245.2B, trading at ₩16980.00 on the KSC. Market cap moves with the live share price.
What is Korea United Pharm's P/E ratio?
Korea United Pharm's trailing twelve-month P/E ratio is 6.4x, with a price-to-book (P/B) of 0.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Korea United Pharm?
Korea United Pharm runs a net profit margin of 13.6%, a gross margin of 58.0%, and an operating margin of 15.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Korea United Pharm generate?
Korea United Pharm reported revenue of ₩288.8B for fiscal year 2025, with net income of ₩38.3B and earnings per share (EPS) of 2614.37. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Korea United Pharm pay a dividend?
Korea United Pharm offers a trailing dividend yield of about 3.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Korea United Pharm financially healthy?
Korea United Pharm carries a debt-to-equity ratio of 0.03x and a current ratio of 3.36x, with a market beta of 0.32. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Korea United Pharm a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Korea United Pharm (033270) the key facts are: market cap ₩245.2B, P/E 6.4x, revenue ₩288.8B, 52-week range 16460-22300. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Korea United Pharm's full fundamentals live
Get Korea United Pharm's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.